Department of Radiotherapy, European Institute of Oncology, Milan, Italy.
Department of Physics, University of Milan, Italy; Unit of Medical Physics, European Institute of Oncology, Milan, Italy.
Radiother Oncol. 2018 Aug;128(2):315-320. doi: 10.1016/j.radonc.2018.06.002. Epub 2018 Jun 23.
Formulation of a global Unified Dosimetry Index (gUDI) for the evaluation of prostate simultaneous integrated boost Volumetric Modulated Arc Therapy (VMAT by RapidArc) radiotherapy plans.
Dose coverage, conformity, homogeneity and dose gradient index could be included in the Unified Dosimetry Index (UDI). We developed a global UDI to evaluate treatment plans containing volumes irradiated with different dose prescriptions: Intensity Modulated Radiation Therapy with simultaneous integrated boost (IMRT-SIB) with 2 dose levels (36.25 Gy/5 fz for the whole prostate gland and 37.5 Gy/5 fz for Dominant Intraprostatic Lesion (DIL)). To validate gUDI scoring system, 65 prostate cancer patients were evaluated. Mean (µ) and standard deviations (σ) were calculated for all dosimetry indices and gUDI. Furthermore, gUDI µ and σ were analyzed to compare and classify treatment plans: plans can be ranked as "excellent", "good", "average" or "poor".
Prostate Dose Gradient, Prostate Conformity and DIL Conformity indices had highlighted a major deviation from ideal scores. gUDI index classification showed most of the plans scored as "average" and "good".
gUDI score can be a useful tool to quantify treatment plans quality also when volumes with different dose-prescription are treated.
制定用于评估前列腺同步整合升压容积调强弧形治疗（RapidArc 下的容积调强放疗）计划的全球统一剂量学指数（gUDI）。
剂量覆盖、适形性、均匀性和剂量梯度指数都可以包含在统一剂量学指数（UDI）中。我们开发了一个全球 UDI 来评估包含不同剂量处方照射体积的治疗计划：具有 2 个剂量水平（全前列腺 36.25Gy/5fz 和优势前列腺内病变 37.5Gy/5fz）的调强放疗同步整合升压（IMRT-SIB）。为了验证 gUDI 评分系统，我们评估了 65 例前列腺癌患者。计算了所有剂量学指标和 gUDI 的平均值（µ）和标准差（σ）。此外，还分析了 gUDIµ和σ，以比较和分类治疗计划：计划可以被评为“优秀”、“良好”、“一般”或“差”。
前列腺剂量梯度、前列腺适形性和 DIL 适形性指数显示出与理想分数的主要偏差。gUDI 指数分类表明，大多数计划的评分是“一般”和“良好”。
gUDI 评分可以作为一种有用的工具，用于量化治疗计划的质量，即使治疗的体积具有不同的剂量处方。
